Impacto da vacinação contra COVID-19 na resposta imunológica: análise de linfócitos e citocinas em profissionais de saúde

##plugins.themes.bootstrap3.article.main##

João Alves Gonçalves Neto
Eduardo Davi Lima da Silva
Heloísa Isabela Leão
Rômulo Pessoa e Silva
Bárbara de Oliveira Silva
Erika da Silva Bezerra de Menezes
Michelle Melgarejo da Rosa
Moacyr Jesus Barreto de Melo Rêgo
Maíra Galdino da Rocha Pitta
Michelly Cristiny Pereira

Resumo

Objetivo: Avaliar o perfil imunológico de linfócitos T e B e citocinas em profissionais de saúde antes e após a vacinação contra a COVID-19. Métodos: Vinte indivíduos saudáveis, que trabalhavam na testagem de COVID-19, foram avaliados com coletas de sangue em seis momentos (T0 a T5). Os níveis de IgG contra SARS-CoV-2 e das interleucinas IL-6, IFN-γ e IL-10 foram medidos por ELISA. A imunofenotipagem de linfócitos foi realizada com anticorpos anti-CD3, anti-CD4 e anti-CD19 via citometria de fluxo (p ≤ 0,05). Resultados: Todos os participantes foram infectados por COVID-19 durante o estudo, e a maioria foi vacinada com CoronaVac e Pfizer. Em T0, 25% apresentavam IgG positivo, atingindo 100% em T3 e T5. As citocinas não variaram significativamente, mas os linfócitos TCD3+ reduziram entre T0 e T3 e T2 e T3. Observou-se diferença em TCD4+ entre T4 e T5 e variação em linfócitos B entre T0 e T5. Conclusão: A presença de IgG em T0 sugeriu exposição prévia ao vírus. Embora as citocinas não tenham mostrado variação significativa, a análise dos linfócitos T e B evidenciou mudanças imunológicas ao longo da vacinação, indicando um efeito modulador no sistema imunológico.

##plugins.themes.bootstrap3.article.details##

Como Citar
Gonçalves NetoJ. A., SilvaE. D. L. da, LeãoH. I., SilvaR. P. e, SilvaB. de O., MenezesE. da S. B. de, RosaM. M. da, RêgoM. J. B. de M., PittaM. G. da R., & PereiraM. C. (2025). Impacto da vacinação contra COVID-19 na resposta imunológica: análise de linfócitos e citocinas em profissionais de saúde. Revista Eletrônica Acervo Saúde, 25(5), e19700. https://doi.org/10.25248/reas.e19700.2025
Seção
Artigos Originais

Referências

1. BAHRINI K, et al. Immune Cell Response during COVID-19 Infection and following SARS-CoV-2 Vaccination in Patients Admitted to Intensive Care Unit. J Immunol Res. 2023;2023.

2. BAROUCH DH. Covid-19 vaccines—immunity, variants, boosters. N Engl J Med. 2022;387(11):1011–20.

3. CHEN S, et al. The role of B cells in COVID-19 infection and vaccination. Front Immunol., 2022; 13: 988536.

4. DEB B, et al. Current global vaccine and drug efforts against COVID-19: Pros and cons of bypassing animal trials. J Biosci. 2020;45:1–10.

5. FAMILIAR-MACEDO D, et al. Inflammatory and cytotoxic mediators in COVID-19 patients and in ChAdOx1 nCoV-19 (AZD1222) vaccine recipients. Cytokine. 2023;171:156350.

6. FIDLER S, et al. Booster vaccination against SARS-CoV-2 induces potent immune responses in people with human immunodeficiency virus. Clin Infect Dis. 2023;76(2):201–9.

7. HAVERVALL S, et al. Impact of SARS‐CoV‐2 infection on vaccine‐induced immune responses over time. Clin Transl Immunol. 2022;11(4).

8. HE F, et al. Coronavirus disease 2019: What we know? J Med Virol. 2020;92(7):719–25.

9. ISLAS-VAZQUEZ L, et al. Effector-memory B-lymphocytes and follicular helper T-lymphocytes as central players in the immune response in vaccinated and nonvaccinated populations against SARS-CoV-2. Vaccines (Basel). 2022;10(10):1761.

10. LI Q, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus–infected pneumonia. N Engl J Med. 2020;382(13):1199–207.

11. LI Z, et al. Characterization of SARS-CoV-2-Specific humoral and cellular immune responses induced by inactivated COVID-19 vaccines in a real-world setting. Front Immunol. 2021;12:802858.

12. MACIEL E, et al. The SARS-CoV-2 vaccination campaign in Brazil and the invisibility of science evidences. Cien Saude Colet. 2022;27:951–6.

13. MANSOURABADI AH, et al. B lymphocytes in COVID-19: a tale of harmony and discordance. Arch Virol. 2023;168(5):148.

14. MINISTÉRIO DA SAÚDE. 11 Edição, Brasília. 2021. Plano Nacional de Operacionalização da Vacinação contra COVID-19.

15. MIRNIA K, et al. Short-term side effects of COVID-19 vaccines among healthcare workers: a multicenter study in Iran. Sci Rep. 2024;14(1):4086.

16. MOLLARASOULI F, et al. A review on coronavirus disease 2019 (COVID-19): current progress, clinical features and bioanalytical diagnostic methods. Microchim Acta. 2022;189(3):103.

17. NERY GB, et al. Impact of social distancing from the COVID-19 pandemic on the immuno-inflammatory response of older adults. BMC Geriatr. 2024;24(1):99.

18. NUÑEZ NG, et al. High-dimensional analysis of 16 SARS-CoV-2 vaccine combinations reveals lymphocyte signatures correlating with immunogenicity. Nat Immunol. 2023;24(6):941–54.

19. SHEHATA AA, et al. Diversity of coronaviruses with particular attention to the interspecies transmission of SARS-CoV-2. Animals. 2022;12(3):378.

20. SINAEI R, et al. Short-term Safety of Covaxin, Sinopharm, Sputnik V, and AstraZeneca COVID-19 Vaccines Among Iranian Healthcare Workers: A Cross-Sectional Study. Arch Clin Infect Dis. 2024;19(1).

21. SOUZA-SILVA GADE, et al. Memory elicitation, T-cell response and antibody production: an independent study of an inactivated entire virus vaccine (Coronavac). An Acad Bras Cienc. 2022;94.

22. V’KOVSKI P, et al. Coronavirus biology and replication: implications for SARS-CoV-2. Nat Rev Microbiol. 2021;19(3):155–70.

23. STRUKCINSKIENE B, et al. Immune Response to COVID-19 Vaccination in Frontline Healthcare Workers. Vaccines. 2024;12(2):199.

24. DORIA-ROSE N, et al. Antibody persistence through 6 months after the second dose of mRNA-1273 vaccine for Covid-19. N Engl J Med. 2021;384(23):2259–61.

25. WORLD HEALTH ORGANIZATION. WHO COVID-19 Dashboard. Geneva: World Health Organization; 2020.

26. ZALEWSKA M, et al. An immune response to heterologous ChAdOx1/BNT162b2 vaccination against COVID-19: evaluation of the anti-RBD specific IgG antibodies titers and interferon gamma release assay (IGRA) test results. Vaccines (Basel). 2022;10(9):1546.

27. NISHIYAMA T, et al. Modeling COVID-19 vaccine booster-elicited antibody response and impact of infection history. Vaccine. 2023;41(52):7655–62.

28. MATSUMOTO N, et al. Longitudinal antibody dynamics after COVID-19 vaccine boosters based on prior infection status and booster doses. Sci Rep. 2024;14(1):4564.

29. PERICO L, et al. Long-term adaptive response in COVID-19 vaccine recipients and the effect of a booster dose. Front Immunol. 2023;14:1123158.

30. DOHERTY INSTITUTE. New analysis predicts how well vaccines will work against COVID-19 strains. 2023. Disponível em: https://www.doherty.edu.au/news-events/news/new-analysis-predicts-how-well-vaccines-will-work-against-covid-19-strains-. Acessado em: 6 fev. 2025.

31. NOTARTE KI, et al. Age, sex and previous comorbidities as risk factors not associated with SARS-CoV-2 infection for long COVID-19: a systematic review and meta-analysis. J Clin Med. 2022;11(24):7314.